European Commission Grants Marketing Authorization for ARIKAYCE® Liposomal 590 mg Nebuliser Dispersion for the Treatment of NTM Lung Infections Caused by MAC in Adult Non-CF Patients with Limited Tre
Go back to European Commission Grants Marketing Authorization for ARIKAYCE® Liposomal 590 mg Nebuliser Dispersion for the Treatment of NTM Lung Infections Caused by MAC in Adult Non-CF Patients with Limited Tre| INSMED (NASDAQ: INSM) | Delayed: 107.00 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $107.00 | 52 Week High | $19.30 | |||
| Open | $107.00 | 52 Week Low | $9.02 | |||
| Day High | $107.00 | P/E | N/A | |||
| Day Low | $107.00 | EPS | $-1.69 | |||
| Volume | 1,229 | |||||
